🧠 AI SUMMARY
Key Clinical Points — generated by Claude AI
✓
Key Clinical Points
✓
What is being tested: Elacestrant (a selective estrogen receptor degrader) combined with everolimus (mTOR inhibitor) in patients with ER+/HER2− advanced breast cancer harbouring ESR1 mutations who have progressed despite prior endocrine therapy and CDK4/6 inhibitors.
✓
Patient eligibility overview: The trial targets a specific population with advanced, treatment-resistant breast cancer defined by hormone receptor status (ER+/HER2−), presence of ESR1 mutations, and documented progression to sequential lines of endocrine therapy plus CDK4/6 inhibitor combinations.
✓
Clinical significance: ESR1 mutations are associated with endocrine resistance and poor prognosis; this trial addresses an unmet need in heavily pre-treated patients by testing a novel mechanistic approach combining receptor degradation with mTOR inhibition, potentially offering benefit to those with limited therapeutic options after standard sequential therapy.
AI-generated summary — verify with registry before clinical use.
Trial Summary
This trial will study a type of advanced breast cancer (ABC) defined as endocrine receptor (ER)-positive/human epidermal growth factor receptor 2(HER2)-negative and estrogen receptor 1 (ESR1)-mutated. Patients will be treated with elacestrant, a compound that acts as a selective estrogen receptor degrader, and everolimus (or placebo), a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer.
The main purpose of the study is to analyze the efficacy (to find out how effective a treatment is) of elacestrant plus everolimus therapy in patients who have ER-positive/HER2-negative, ESR1-mutated, ABC progressing to endocrine therapy and cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. The efficacy of elacestrant plus everolimus combination will be determined by assessing the period from elacestrant plus everolimus (or placebo) treatment initiation until to the first occurrence of disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason, whichever occurs first, defined as progression free survival.
Rigorous eligibility criteria based on specific co-morbidities and clinicopathologic features of their disease have been designed to minimize the risk of patients participating in this study. The anticipated favorable clinical benefits of elacestrant combined with everolimus are projected to outweigh the risks of this treatment. This study will be performed in full compliance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and all applicable local Good Clinical Practice (GCP) and regulations.
Sponsor: MedSIR
Participants: ALL
Start: 2024-12-05
Completion: 2027-09
Min Age: 18 Years
Eligibility Criteria
Inclusion Criteria: Patients will be included in the study only if they meet ALL of the following criteria: 1. Patient must be capable to understand the purpose of the study and have signed written informed consent form (ICF) prior to beginning specific protocol procedures. 2. Female or male patients ≥ 18 years of age at the time of signing ICF. 3. Pre- or perimenopausal women, who do not meet the criteria for post-menopausal status (defined in continuation) and men must be concurrently receiving a LHRH analogue for at least 28 days (if shorter, post-menopausal levels of serum estradiol/follicle-stimulating hormone [FSH] must be confirmed analytically) prior to study randomization and are planning to continue LHRH agonist treatment during the study. Post-menopausal women as defined by any of the following criteria: 1. Age ≥ 60 years; 2. Age < 60 years and cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and serum estradiol and/or FSH levels within the laboratory's reference range for post-menopausal females; 3. Documented bilateral surgical oophorectomy. 4. Histologically- or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of either unresectable locally recurrent or metastatic disease confirmed by computerized…